[show abstract]
[hide abstract]
ABSTRACT: Neurotoxicity is a common adverse effect of cyclosporine (CsA) in transplant recipients. Although most patients develop mild toxic manifestations, leukoencephalopathy with seizures, visual complications, psychiatric symptoms and motor and speech disorders may occur. Whether everolimus exacerbates the neurotoxicity of CsA is not known. We describe a patient who developed severe neurologic complications, consistent with CsA-induced neurotoxicity, developing 7.5 years after cardiac transplantation, 3 months after everolimus was added to the immunosuppressive regimen.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 07/2007; 26(6):661-4. · 3.54 Impact Factor
